IMPROVING OLIGONUCLEOTDE MANUFACTURE WITH STIRRED BED

Oligonucleotide-based active pharmaceutical ingredients (APIs) have emerged as a powerful approach to treating diseases. With hundreds of them in advanced clinical trials, a potential metric ton demand for certain products is expected that might not be easily fulfilled by conventional solid phase oligonucleotide synthesis (SPOS). It is essential to develop more efficient, more sustainable, and highly scalable manufacturing techniques.This whitepaper explains how the innovative stirred-bed technology (SBT) for SPOS fulfills all these requirements and represents an economical engineering solution with a simple reactor design and adapted chemistry. Thus, ton-scale commercial oligonucleotide API manufacture with unmatched process mass intensity is within reach.Key Highlights:Innovative Manufacturing Techniques: Learn how stirred-bed technology (SBT) offers a more efficient and scalable alternative to traditional solid-phase oligonucleotide synthesis (SPOS), enabling the production of metric ton quantities of oligonucleotides.Enhanced Process Efficiency: Understand the significant improvements in process mass intensity (PMI), solvent consumption, and overall productivity achieved through SBT.Sustainable Solutions: Explore how SBT reduces the environmental footprint of oligonucleotide manufacturing by minimizing the use of hazardous reagents and solvents.High Purity and Yield: See how Bachem’s optimized detritylation chemistry and on-resin modifications ensure high purity and yield in oligonucleotide production. To download the entire resource, please complete the form.The post IMPROVING OLIGONUCLEOTDE MANUFACTURE WITH STIRRED BED appeared first on Bachem.Weiter zum vollständigen Artikel bei Bachem Holding AG Weiter zum vollständigen Artikel bei Bachem Holding AG